Agent for treating myelofibrosis

A technology of bone marrow and targeting agent, which is applied in bone diseases, biochemical equipment and methods, active ingredients of hydroxyl compounds, etc. Effect

Active Publication Date: 2011-08-03
NITTO DENKO CORP
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, none of these agents is satisfactory yet, and further development of therapeutic agents for myelofibrosis is required

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for treating myelofibrosis
  • Agent for treating myelofibrosis
  • Agent for treating myelofibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0101] Example 1 : Confirmation of pathological state in mouse model of myelofibrosis

[0102] As a mouse model of myelofibrosis, a transgenic mouse for thrombopoietin (TPO) developed by Dr. Kazuya Shimoda and Dr. Mine Harada (hereinafter also referred to as TPO mouse (see Leukemia Research 29:761-769, 2005)) was used. . In this mouse, due to the excessive production of TPO by TPO gene-introduced cells, the number of megakaryocytes in the bone marrow increases, and the increased megakaryocytes excessively produce transforming growth factor-beta (TGF-beta), which stimulates bone marrow fibrosis. cells, promote the collagen secretion of fibroblasts, and cause myelofibrosis (refer to figure 2 ).

[0103] TPO mice (supplied by the Experimental Facility Department of Kyushu University) were fed with the usual feeding conditions, the mice were euthanized at 4, 7, 9 or 12 months after birth, bone marrow was collected and tissue samples were prepared, and hematoxylin and eosin ( ...

Embodiment 2

[0108] Example 2 : Production of siRNA

[0109]siRNA targeting mouse HSP47 (HSP47 siRNA) was prepared as a drug for inhibiting the activity of extracellular matrix-producing cells in bone marrow. Specifically, five kinds of HSP47 siRNAs (HSP47 siRNA-A to E) and random siRNAs (Random siRNA) having the following sequences were prepared and used in subsequent experiments. Among them, HSP47 siRNA was purchased from iGENE Co., Ltd. (Tokyo) (the target sequence of HSP47 siRNA was designed according to the database Refseq (GenBank Accession No. NM_009825) registered in November 2006). Random siRNA was also purchased from iGENE Corporation (trade name: dsRNA scramble).

[0110] HSP47 siRNA-A: 5'-UGGAUGGGAAAGAUGCAGAAGAAGGAG-3' (sense, sequence number: 1)

[0111] 3'-UAACCUACCCUUUCUACGUCUUCUUCC-5' (antisense, serial number: 2)

[0112] HSP47 siRNA-B: 5'-UGUCUGAGUGGGUAUUUUUAGACAGAG-3' (sense, sequence number: 3)

[0113] 3'-UAACAGACUCACCCAUAAAAAUCUGUC-5' (antisense, sequence number...

Embodiment 3

[0123] Example 3 : Properties of primary cultured bone marrow fibroblasts from TPO mice

[0124] Bone marrow cells from TPO mice aged 4 to 6 weeks were cultured in MEM (Minimum Essential Medium Eagle, Sigma) supplemented with 15% fetal calf serum (FCS) for 4 weeks to obtain primary cultured cells. bone marrow fibroblasts. Figure 6 The cell morphology observed under an inverted microscope is shown, and the cells are typical spindle-shaped fibroblasts. Figure 7 Flow cytometry using the respective antibodies (anti-Vimentin antibody (Santa Cruz Biotechnology), anti-αSMA antibody (Santa Cruz Biotechnology)) was used to analyze the expression of markers vimentin (Vimentin) and αSMA in mesenchymal cells As a result, we can see the expressions of the two. This result shows that the cells cultured above are typical bone marrow fibroblasts. Wherein, the flow cytometer used for analysis is FACS calibur (Becton Dickinson Company), and the measurement data is analyzed using CellQues...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed is a substance delivery carrier for an extracellular-matrix-producing cell in the bone marrow, which comprises a retinoid. Also disclosed is an agent for treating myelofibrosis by utilizing a substance capable of regulating the activity or proliferation of an extracellular-matrix-producing cell in the bone marrow.

Description

technical field [0001] The present invention relates to a substance delivery carrier targeting extracellular matrix-producing cells in bone marrow, a drug for controlling the activity or proliferation of extracellular matrix-producing cells in bone marrow, and a treatment agent for myelofibrosis and myelofibrosis processing method. Background technique [0002] Myelofibrosis is a general term for diseases that cause widespread diffuse fibrosis in the bone marrow, including primary myelofibrosis of unknown cause and secondary myelofibrosis in the presence of an underlying disease. [0003] Primary myelofibrosis is characterized by fibrosis of the bone marrow throughout the body and extramedullary hematopoiesis in the liver and spleen, and leukoerythroblastosis of granulocytes and erythrocytes in peripheral blood, which belongs to chronic myeloid proliferation disease. The true state of primary myelofibrosis is the proliferation of monoclonal hematopoietic cells caused by ge...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/10A61K9/127A61K31/7105A61K45/00A61K48/00A61P7/00A61P19/00A61P43/00
CPCC12N15/113C12N2320/32A61K31/07C12N2310/14A61K31/7105A61K9/1272A61K47/48815C12N15/111A61K47/48107A61K45/06A61K47/551A61K47/6911A61P19/00A61P19/04A61P19/08A61P35/00A61P43/00A61P7/00A61K2300/00
Inventor 新津洋司郎松永卓也
Owner NITTO DENKO CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap